Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company's pipeline comprise SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA. It has collaboration agreements with Nationwide Children's Hospital to advance micro-dystrophin gene therapy program under the research and license option agreement; Galgt2, a gene therapy program for the treatment of DMD; and Neutrophin 3, a gene therapy program to treat Charcot-Marie-Tooth neuropathies. The company also has a license agreement with Lysogene to develop LYS-SAF302, a gene therapy for mucopolysaccharidosis IIIA; a license and option agreement with Lacerta to develop treatments for CNS-targeted and lysosomal storage diseases; and research collaboration and option agreement with Genethon to develop micro-dystrophin gene therapy products. In addition, it has a research agreement with Duke University to advance gene editing CRISPR/Cas9 technology for restoring dystrophin expression; a collaboration agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline; a strategic collaboration with Paragon Bioservices; and a strategic collaboration with CENTOGENE for the identification of patients with DMD in the Middle East and North Africa region. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-274-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$301.03 million
Profitability
Miscellaneous
Employees499
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions
What is Sarepta Therapeutics' stock symbol?
Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."
How were Sarepta Therapeutics' earnings last quarter?
Sarepta Therapeutics Inc (NASDAQ:SRPT) posted its quarterly earnings data on Wednesday, May, 8th. The biotechnology company reported ($1.07) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($2.05) by $0.98. The biotechnology company had revenue of $87.01 million for the quarter, compared to analysts' expectations of $86.92 million. Sarepta Therapeutics had a negative net margin of 124.66% and a negative return on equity of 36.26%. View Sarepta Therapeutics' Earnings History.
When is Sarepta Therapeutics' next earnings date?
What price target have analysts set for SRPT?
25 equities research analysts have issued twelve-month price objectives for Sarepta Therapeutics' shares. Their predictions range from $165.00 to $270.00. On average, they expect Sarepta Therapeutics' share price to reach $203.00 in the next twelve months. This suggests a possible upside of 66.9% from the stock's current price. View Analyst Price Targets for Sarepta Therapeutics.
What is the consensus analysts' recommendation for Sarepta Therapeutics?
25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 25 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sarepta Therapeutics.
What are Wall Street analysts saying about Sarepta Therapeutics stock?
Here are some recent quotes from research analysts about Sarepta Therapeutics stock:
- 1. According to Zacks Investment Research, "Sarepta's Exondys 51 has witnessed impressive growth in 2018. Sarepta is also focused on reimbursement programs for better accessibility of the drug. Moreover, a potential approval to golodirsen will boost the company’s prospect as it will increase eligible patient population. Sarepta’s continues to progress with its DMD pipeline. The company is collaborating with companies and academic institutions to boost its DMD pipeline. However, dependence on a single product, Exondys 51, remains a concern. Meanwhile in December 2018, the company received a setback as it failed to gain approval for Exondys 51 in the EU. The DMD market is getting competitive as several other companies are developing therapies. The company’s shares have underperformed the industry so far this year. Loss estimates have narrowed ahead of the company’s Q1 earnings release. The company has a mixed record of earnings surprises in the recent quarters." (5/8/2019)
- 2. Cantor Fitzgerald analysts commented, ": Reiterate our Overweight rating and 12-mo. PT of $217. From our conversations with investors, we believe that awareness on limb girdle is increasing, but it remains low. We are publishing our 35-page prep pack discussing the disease, data expectations and potential stock moves. Sarepta will disclose 60- day biopsy data for MYO-101 in LGMD2E patients on Wed. morning (2/27). This is the first of five limb girdle readouts in the pipeline, which we think could drive significant upside to current valuation and diversify Sarepta beyond DMD. Sarepta remains a top pick." (2/22/2019)
- 3. HC Wainwright analysts commented, "Our $267 price target is derived from a risk-adjusted (does not include CMT or Sanfilippo A) DCF analysis and is based on: beta of 1.42, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 7.4%, and tax rate of 15% beginning in FY 2024." (1/4/2019)
Has Sarepta Therapeutics been receiving favorable news coverage?
Media coverage about SRPT stock has been trending very negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sarepta Therapeutics earned a media sentiment score of -3.8 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of Sarepta Therapeutics' key competitors?
Some companies that are related to Sarepta Therapeutics include Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Takeda Pharmaceutical (TAK), ASTELLAS PHARMA/ADR (ALPMY), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GNMSF), Mylan (MYL), Ionis Pharmaceuticals (IONS), Ono Pharmaceutical (OPHLF), SAGE Therapeutics (SAGE), Bausch Health Companies (BHC) and Jazz Pharmaceuticals (JAZZ).
What other stocks do shareholders of Sarepta Therapeutics own?
Who are Sarepta Therapeutics' key executives?
Sarepta Therapeutics' management team includes the folowing people:
- Mr. Douglas S. Ingram, Pres, CEO & Director (Age 56)
- Mr. Sandesh Mahatme LL.M., Exec. VP, CFO & Chief Bus. Officer (Age 54)
- Mr. David Tyronne Howton Jr., Exec. VP, Gen. Counsel & Corp. Sec. (Age 47)
- Mr. Alexander Bo Cumbo, Exec. VP & Chief Commercial Officer (Age 48)
- Dr. Edward M. Kaye, Advisor (Age 70)
Who are Sarepta Therapeutics' major shareholders?
Sarepta Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (3.74%), FIL Ltd (1.66%), TimesSquare Capital Management LLC (1.48%), Jennison Associates LLC (1.36%), Gilder Gagnon Howe & Co. LLC (1.34%) and Eagle Asset Management Inc. (1.23%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Edward M Md Kaye, Hans Lennart Rudolf Wigzell, Richard Barry, Sandesh Mahatme and Shamim Ruff. View Institutional Ownership Trends for Sarepta Therapeutics.
Which major investors are selling Sarepta Therapeutics stock?
SRPT stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, First Trust Advisors LP, Carillon Tower Advisers Inc., Eagle Asset Management Inc., Macquarie Group Ltd., Chartwell Investment Partners LLC, Bank of Montreal Can and Emerald Advisers LLC. Company insiders that have sold Sarepta Therapeutics company stock in the last year include Alexander Cumbo, David T Howton, Hans Lennart Rudolf Wigzell, Richard Barry and Sandesh Mahatme. View Insider Buying and Selling for Sarepta Therapeutics.
Which major investors are buying Sarepta Therapeutics stock?
SRPT stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, OppenheimerFunds Inc., Cadian Capital Management LP, TimesSquare Capital Management LLC, Columbus Circle Investors, Candriam Luxembourg S.C.A., Creative Planning and Marshall Wace North America L.P.. View Insider Buying and Selling for Sarepta Therapeutics.
How do I buy shares of Sarepta Therapeutics?
Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sarepta Therapeutics' stock price today?
One share of SRPT stock can currently be purchased for approximately $121.62.
How big of a company is Sarepta Therapeutics?
Sarepta Therapeutics has a market capitalization of $9.02 billion and generates $301.03 million in revenue each year. The biotechnology company earns $-361,920,000.00 in net income (profit) each year or ($5.46) on an earnings per share basis. Sarepta Therapeutics employs 499 workers across the globe.
What is Sarepta Therapeutics' official website?
How can I contact Sarepta Therapeutics?
Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-274-4000 or via email at [email protected]
MarketBeat Community Rating for Sarepta Therapeutics (NASDAQ SRPT)
MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote "Outperform" if you believe SRPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
